BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36533975)

  • 21. Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry.
    Michelena X; López-Medina C; Erra A; Juanola X; Font-Ugalde P; Collantes E; Marzo-Ortega H
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
    Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
    Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures?
    Nannini C; Cantini F; Niccoli L; Cassarà E; Salvarani C; Olivieri I; Lally EV
    Arthritis Rheum; 2009 Jun; 61(6):801-12. PubMed ID: 19479708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
    Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating to Target(s) With Interleukin-17 Inhibitors.
    Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
    J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study.
    Grellmann C; Dombrowsky W; Fabricius V; Suruki R; Sheahan A; Joeres L
    Adv Ther; 2021 Jan; 38(1):366-385. PubMed ID: 33128201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
    Gottlieb AB; Deodhar A; Mcinnes IB; Baraliakos X; Reich K; Schreiber S; Bao W; Marfo K; Richards HB; Pricop L; Shete A; Trivedi V; Keefe D; Papavassilis CC; Jagiello P; Papanastasiou P; Mease PJ; Lebwohl M
    Acta Derm Venereol; 2022 Apr; 102():adv00698. PubMed ID: 35146532
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Iwaszko M; Wielińska J; Świerkot J; Kolossa K; Sokolik R; Bugaj B; Chaszczewska-Markowska M; Jeka S; Bogunia-Kubik K
    Front Immunol; 2021; 12():631603. PubMed ID: 34177886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation of NSAIDs, DMARDs, and TNF Inhibitors for Ankylosing Spondylitis and Psoriatic Arthritis to Risk of Total Hip and Knee Arthroplasty.
    Stovall R; Peloquin C; Felson D; Neogi T; Dubreuil M
    J Rheumatol; 2021 Jul; 48(7):1007-1013. PubMed ID: 33452168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study.
    Aydin V; Akici A; Isli F; Aksoy M; Aydin M; Gursoz H
    J Clin Pharm Ther; 2019 Aug; 44(4):553-560. PubMed ID: 30763469
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Larid G; Delwail A; Dalle T; Vasseur P; Silvain C; Jégou JF; Morel F; Lecron JC; Gervais E
    Front Immunol; 2022; 13():993363. PubMed ID: 36426370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study.
    Ahmed N; Prior JA; Chen Y; Hayward R; Mallen CD; Hider SL
    Clin Rheumatol; 2016 Dec; 35(12):3069-3073. PubMed ID: 27485152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy.
    Kim HA; Lee E; Park SY; Lee SS; Shin K
    J Korean Med Sci; 2022 Aug; 37(33):e253. PubMed ID: 35996930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
    Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
    Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
    Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
    Xie Y; Liu Y
    Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing.
    Su YJ
    Clin Rheumatol; 2020 Dec; 39(12):3677-3684. PubMed ID: 32468320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
    Emond B; Ellis LA; Chakravarty SD; Ladouceur M; Lefebvre P
    Curr Med Res Opin; 2019 Oct; 35(10):1751-1759. PubMed ID: 31106607
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.